E2F1 promotes angiogenesis through the VEGF-C/VEGFR-3 axis in a feedback loop for cooperative induction of PDGF-B

Journal of Molecular Cell Biology

Volumn 5, Issue 6, 2013, Pages 391-403

  Engelmann, David ^a   Mayoli Nüssle, Deborah ^a   Mayrhofer, Christian ^a   Fürst, Katharina ^a   Alla, Vijay ^a   Stoll, Anja ^a   Spitschak, Alf ^a   Abshagen, Kerstin ^a   Vollmar, Brigitte ^a   Ran, Sophia ^b   Pützer, Brigitte M ^a  

^a ROSTOCK UNIVERSITY MEDICAL CENTER   (Germany)

^b SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

E2F1; Hypoxia; Neovascularization; PDGF B; Regulatory feedback loop; VEGF C; VEGFR 3

Indexed keywords

PLATELET DERIVED GROWTH FACTOR B; TRANSCRIPTION FACTOR E2F1; VASCULOTROPIN C; VASCULOTROPIN RECEPTOR 3;

ANGIOGENESIS; ARTICLE; CAPILLARY TUBE; FEEDBACK SYSTEM; HUMAN; NEOVASCULARIZATION (PATHOLOGY); POSITIVE FEEDBACK; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; REGULATORY MECHANISM; UPREGULATION;

E2F1; HYPOXIA; NEOVASCULARIZATION; PDGF-B; REGULATORY FEEDBACK LOOP; VEGF-C; VEGFR-3;

ANIMALS; CELL LINE; CELL LINE, TUMOR; CHROMATIN IMMUNOPRECIPITATION; E2F1 TRANSCRIPTION FACTOR; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOBLOTTING; MALE; MICE; NEOVASCULARIZATION, PATHOLOGIC; PROTO-ONCOGENE PROTEINS C-SIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR C; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3;

EID: 84890330004     PISSN: 16742788     EISSN: 17594685     Source Type: Journal    
DOI: 10.1093/jmcb/mjt035     Document Type: Article

References (46)

1. Abdollahi, A., and Folkman, J. (2010). Evading tumor evasion: current concepts and perspectives of anti-angiogenic cancer therapy. Drug Resist. Updat. 13, 16-28.
2. Abshagen, K., Schrodi, I., Gerber, T., et al. (2009). In vivo analysis of biocompatibility and vascularization of the synthetic bone grafting substitute Nano Bone. J. Biomed. Mater. Res. A 91, 557-566.
3. Alla, V., Engelmann, D., Niemetz, A., et al. (2010). E2F1 inmelanoma progression and metastasis. J. Natl Cancer Inst. 102, 127-133.
4. Alla, V., Kowtharapu, B.S., Engelmann, D., et al. (2012). E2F1 confers anticancer drug resistance by targeting ABC transporter family members and Bcl-2 via the p73/DNp73-miR-205 circuitry. Cell Cycle 11, 3067-3078.
5. Battegay, E.J., Rupp, J., Iruela-Arispe, L., et al. (1994). PDGF-BB modulates endothelial proliferation and angiogenesis in vitro via PDGF beta-receptors. J. Cell Biol. 125, 917-928.
6. Bergers, G., and Hanahan, D. (2008). Modes of resistance to anti-angiogenic therapy. Nat. Rev. Cancer 8, 592-603.
7. Chen, D., Pacal, M., Wenzel, P., et al. (2009a). Division and apoptosis of E2f-deficient retinal progenitors. Nature 462, 925-929.
8. Chen, H.Z., Tsai, S.Y., and Leone, G. (2009b). Emerging roles of E2Fs in cancer: an exit from cell cycle control. Nat. Rev. Cancer 9, 785-797.
9. Chien, M.H., Ku, C.C., Johansson, G., et al. (2009). Vascular endothelial growth factor-C (VEGF-C) promotes angiogenesis by induction of COX-2 in leukemic cells via the VEGF-R3/JNK/AP-1 pathway. Carcinogenesis 30, 2005-2013.
10. Donnem, T., Al-Saad, S., Al-Shibli, K., et al. (2010). Co-expression of PDGF-B and VEGFR-3 strongly correlates with lymph node metastasis and poor survival in non-small-cell lung cancer. Ann. Oncol. 21, 223-231.
11. Engelmann, D., and Putzer, B.M. (2010). Translating DNA damage into cancer cell death-Aroadmap for E2F1 apoptotic signalling and opportunities fornewdrug combinations to overcome chemoresistance. Drug Resist. Updat. 13, 119-131.
12. Engelmann, D., and Putzer, B.M. (2012). The dark side of E2F1: in transit beyond apoptosis. Cancer Res. 72, 571-575.
13. Engelmann, D., Knoll, S., Ewerth, D., et al. (2010). Functional interplay between E2F1 and chemotherapeutic drugs defines immediate E2F1 target genes crucial for cancer cell death. Cell. Mol. Life Sci. 67, 931-948.
14. Flister, M.J., Wilber, A., Hall, K.L., et al. (2010). Inflammation induces lymphangiogenesis through up-regulation of VEGFR-3 mediated by NF-kappaB and Prox1. Blood 115, 418-429.
15. Fontemaggi, G., Dell'Orso, S., Trisciuoglio, D., et al. (2009). The execution of the transcriptional axis mutant p53, E2F1 and ID4 promotes tumor neo-angiogenesis. Nat. Struct. Mol. Biol. 16, 1086-1093.
16. Goukassian, D.A., Kishore, R., Krasinski, K., et al. (2003). Engineering the response to vascular injury: divergent effects of deregulated E2F1 expression on vascular smooth muscle cells and endothelial cells result in endothelial recovery and inhibition of neointimal growth. Circ. Res. 93, 162-169.
17. Guo, P., Hu, B., Gu, W., et al. (2003). Platelet-derived growth factor-B enhances glioma angiogenesis by stimulating vascular endothelial growth factor expression in tumor endothelia and by promoting pericyte recruitment. Am. J. Pathol. 162, 1083-1093.
18. Han, S., Park, K., Bae, B.N., et al. (2003). E2F1 expression is related with the poor survival of lymph node-positive breast cancer patients treated with fluorouracil, doxorubicin and cyclophosphamide. Breast Cancer Res. Treat. 82, 11-16.
19. Hanada, N., Lo, H.W., Day, C.P., et al. (2006). Co-regulation of B-Myb expression by E2F1 and EGF receptor. Mol. Carcinog. 45, 10-17.
20. Imai, M.A., Oda, Y., Oda, M., et al. (2004). Overexpression of E2F1 associated with LOH at RB locus and hyperphosphorylation of RB in non-small cell lung carcinoma. J. Cancer Res. Clin. Oncol. 130, 320-326.
21. John, K., Alla, V., Meier, C., et al. (2011). GRAMD4 mimics p53 and mediates the apoptotic function of p73 at mitochondria. Cell Death Differ. 18, 874-886.
22. Johnson, J.L., Pillai, S., Pernazza, D., et al. (2012). Regulation of matrix metalloproteinase genes by E2F transcription factors: Rb-Raf-1 interaction as a novel target for metastatic disease. Cancer Res. 72, 516-526.
23. Kaipainen, A., Korhonen, J., Mustonen, T., et al. (1995). Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc. Natl Acad. Sci. USA 92, 3566-3570.
24. Kalashnikova, E.V., Revenko, A.S., Gemo, A.T., et al. (2010). ANCCA/ATAD2 overexpression identifies breast cancer patients with poor prognosis, acting to drive proliferation and survival of triple-negative cells through control of B-Myb and EZH2. Cancer Res. 70, 9402-9412.
25. Karkkainen, M.J., Ferrell, R.E., Lawrence, E.C., et al. (2000). Missense mutations interfere with VEGFR-3 signalling in primary lymphoedema. Nat. Genet. 25, 153-159.
26. Kurenova, E.V., Hunt, D.L., He, D., et al. (2009). Vascular endothelial growth factor receptor-3 promotes breast cancer cell proliferation, motility and survival in vitro and tumor formation in vivo. Cell Cycle 8, 2266-2280.
27. Laakkonen, P., Waltari, M., Holopainen, T., et al. (2007). Vascular endothelial growth factor receptor 3 is involved in tumor angiogenesis and growth. Cancer Res. 67, 593-599.
28. Lee, J.S., Leem, S.H., Lee, S.Y., et al. (2010). Expression signature of E2F1 and its associated genes predict superficial to invasive progression of bladder tumors. J. Clin. Oncol. 28, 2660-2667.
29. Lo, H.W., and Hung, M.C. (2006). Nuclear EGFR signalling network in cancers: linking EGFR pathway to cell cycle progression, nitric oxide pathway and patient survival. Br. J. Cancer 94, 184-188.
30. Merdzhanova, G., Gout, S., Keramidas, M., et al. (2010). The transcription factor E2F1 and the SR protein SC35 control the ratio of pro-angiogenic versus antiangiogenic isoforms of vascular endothelial growth factor-A to inhibit neovascularization in vivo. Oncogene 29, 5392-5403.
31. Millour, J., de Olano, N., Horimoto, Y., et al. (2011). ATM and p53 regulate FOXM1 expression via E2F in breast cancer epirubicin treatment and resistance. Mol. Cancer Ther. 10, 1046-1058.
32. Onimaru, M., Yonemitsu, Y., Fujii, T., et al. (2009). VEGF-C regulates lymphangiogenesis and capillary stability by regulation of PDGF-B. Am. J. Physiol. Heart Circ. Physiol. 297, H1685-H1696.
33. Pillai, S., Kovacs, M., and Chellappan, S. (2010). Regulation of vascular endothelial growth factor receptors by Rb and E2F1: role of acetylation. Cancer Res. 70, 4931-4940.
34. Putzer, B.M., and Engelmann, D. (2013). E2F1 apoptosis counterattacked: evil strikes back. Trends Mol. Med. 19, 89-98.
35. Qin, G., Kishore, R., Dolan, C.M., et al. (2006). Cell cycle regulator E2F1 modulates angiogenesis via p53-dependent transcriptional control of VEGF. Proc. Natl Acad. Sci. USA 103, 11015-11020.
36. Revenko, A.S., Kalashnikova, E.V., Gemo, A.T., et al. (2010). Chromatin loading of E2F-MLL complex by cancer-associated coregulator ANCCA via reading a specific histone mark. Mol. Cell. Biol. 30, 5260-5272.
37. Santos, S.C., Miguel, C., Domingues, I., et al. (2007). VEGF and VEGFR-2 (KDR) internalization is required for endothelial recovery during wound healing. Exp. Cell Res. 313, 1561-1574.
38. Sapoznik, S., Cohen, B., Tzuman, Y., et al. (2009). Gonadotropin- regulated lymphangiogenesis in ovarian cancer is mediated by LEDGF-induced expression of VEGF-C. Cancer Res. 69, 9306-9314.
39. Sharma, A., Yeow, W.S., Ertel, A., et al. (2010). The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression. J. Clin. Invest. 120, 4478-4492.
40. Simiantonaki, N., Jayasinghe, C., Michel-Schmidt, R., et al. (2008). Hypoxiainduced epithelial VEGF-C/VEGFR-3 upregulation in carcinoma cell lines. Int. J. Oncol. 32, 585-592.
41. Skobe, M., Hawighorst, T., Jackson, D.G., et al. (2001). Induction of tumor lymphangiogenesisby VEGF-Cpromotesbreast cancermetastasis. Nat. Med.7,192-198.
42. Stanelle, J., Stiewe, T., Theseling, C.C., et al. (2002). Gene expression changes in response to E2F1 activation. Nucleic Acids Res. 30, 1859-1867.
43. Su, J.L., Yang, P.C., Shih, J.Y., et al. (2006). The VEGF-C/Flt-4 axis promotes invasion and metastasis of cancer cells. Cancer Cell 9, 209-223.
44. Su, J.L., Yen, C.J., Chen, P.S., et al. (2007). The role of the VEGF-C/VEGFR-3 axis in cancer progression. Br. J. Cancer 96, 541-545.
45. Suzuki, H., Watabe, T., Kato, M., et al. (2005). Roles of vascular endothelial growth factor receptor 3 signaling in differentiation of mouse embryonic stem cell-derived vascular progenitor cells into endothelial cells. Blood 105, 2372-2379.
46. Tammela, T., Zarkada, G., Wallgard, E., et al. (2008). Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation. Nature 454, 656-660.